[go: up one dir, main page]

PE20151424A1 - Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales - Google Patents

Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales

Info

Publication number
PE20151424A1
PE20151424A1 PE2015001180A PE2015001180A PE20151424A1 PE 20151424 A1 PE20151424 A1 PE 20151424A1 PE 2015001180 A PE2015001180 A PE 2015001180A PE 2015001180 A PE2015001180 A PE 2015001180A PE 20151424 A1 PE20151424 A1 PE 20151424A1
Authority
PE
Peru
Prior art keywords
disease
neurodegenerative
cognitive
prevention
treatment
Prior art date
Application number
PE2015001180A
Other languages
English (en)
Inventor
Tilborg Reiner Van
Original Assignee
Cesa Alliance Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cesa Alliance Sa filed Critical Cesa Alliance Sa
Publication of PE20151424A1 publication Critical patent/PE20151424A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/46—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a un compuesto farmaceutico que tiene la Formula (1); o una sal farmaceuticamente aceptable del mismo, para su uso en la prevencion o el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales tal como la enfermedad de Alzheimer, una composicion farmaceutica y un metodo de preparacion de una composicion farmaceutica
PE2015001180A 2012-12-31 2013-12-17 Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales PE20151424A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LU92126A LU92126B1 (fr) 2012-12-31 2012-12-31 Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale

Publications (1)

Publication Number Publication Date
PE20151424A1 true PE20151424A1 (es) 2015-10-15

Family

ID=47470067

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001180A PE20151424A1 (es) 2012-12-31 2013-12-17 Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales

Country Status (28)

Country Link
US (2) US9284250B2 (es)
EP (1) EP2938337A1 (es)
JP (1) JP6699961B2 (es)
KR (1) KR102104155B1 (es)
CN (1) CN104884052B (es)
AR (1) AR094318A1 (es)
AU (1) AU2013369491B2 (es)
BR (1) BR112015015509B1 (es)
CA (1) CA2895429C (es)
CL (1) CL2015001881A1 (es)
EA (1) EA029650B1 (es)
HK (1) HK1214517A1 (es)
IL (1) IL239622B (es)
JO (1) JO3483B1 (es)
LU (1) LU92126B1 (es)
MA (1) MA38307B1 (es)
MX (1) MX369590B (es)
MY (1) MY171832A (es)
NZ (1) NZ710131A (es)
PE (1) PE20151424A1 (es)
PH (1) PH12015501402B1 (es)
SG (1) SG11201504744WA (es)
TN (1) TN2015000275A1 (es)
TW (1) TWI590819B (es)
UA (1) UA117822C2 (es)
UY (1) UY35253A (es)
WO (1) WO2014102090A1 (es)
ZA (1) ZA201505057B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151433A1 (es) 2012-12-21 2015-10-16 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos
JP6986288B2 (ja) * 2017-01-13 2021-12-22 ベネド バイオメディカル カンパニー リミテッド 新規乳酸菌およびその応用
KR102017415B1 (ko) * 2018-02-13 2019-09-02 연세대학교 산학협력단 뇌 신경 손상 완화용 조성물
CN108813453A (zh) * 2018-05-23 2018-11-16 青岛大学 一种防治帕金森病的食用组合物
WO2021110684A1 (en) 2019-12-02 2021-06-10 Philip Morris Products S.A. Shisha device with trough

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1261572A4 (en) * 2000-03-10 2004-05-26 Applied Genetics Inc Dermatics DERMATOLOGICAL COMPOUNDS
CN1511520A (zh) * 2002-12-31 2004-07-14 �й�ҽѧ��ѧԺҩ���о��� 丁二酸酯衍生物治疗痴呆症的用途
CA2518886A1 (en) * 2003-03-14 2004-09-23 Merck Sharp & Dohme Limited Method for treating mild cognitive impairment and for preventing or delaying alzheimer's disease

Also Published As

Publication number Publication date
KR102104155B1 (ko) 2020-04-24
IL239622B (en) 2018-12-31
US20160194266A1 (en) 2016-07-07
UY35253A (es) 2014-07-31
BR112015015509A2 (pt) 2017-07-11
PH12015501402A1 (en) 2015-09-07
US9611205B2 (en) 2017-04-04
WO2014102090A1 (en) 2014-07-03
IL239622A0 (en) 2015-08-31
AR094318A1 (es) 2015-07-29
KR20150102117A (ko) 2015-09-04
MX2015008520A (es) 2015-09-10
JP2016505600A (ja) 2016-02-25
ZA201505057B (en) 2016-07-27
CL2015001881A1 (es) 2015-11-06
LU92126B1 (fr) 2014-07-01
MA38307A1 (fr) 2016-12-30
US20150361020A1 (en) 2015-12-17
PH12015501402B1 (en) 2015-09-07
AU2013369491B2 (en) 2018-04-26
EA201591021A1 (ru) 2016-01-29
CN104884052A (zh) 2015-09-02
AU2013369491A2 (en) 2015-08-13
HK1214517A1 (zh) 2016-07-29
UA117822C2 (uk) 2018-10-10
TW201431550A (zh) 2014-08-16
NZ710131A (en) 2019-08-30
CA2895429C (en) 2019-04-16
MA38307B1 (fr) 2017-11-30
EP2938337A1 (en) 2015-11-04
US9284250B2 (en) 2016-03-15
SG11201504744WA (en) 2015-07-30
BR112015015509B1 (pt) 2021-11-30
CN104884052B (zh) 2021-06-25
MY171832A (en) 2019-11-01
MX369590B (es) 2019-11-13
TWI590819B (zh) 2017-07-11
CA2895429A1 (en) 2014-07-03
JO3483B1 (ar) 2020-07-05
JP6699961B2 (ja) 2020-05-27
AU2013369491A1 (en) 2015-08-06
EA029650B1 (ru) 2018-04-30
TN2015000275A1 (fr) 2016-10-03

Similar Documents

Publication Publication Date Title
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
NZ702663A (en) Nuclear transport modulators and uses thereof
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
PL2892563T3 (pl) Kompozycje farmaceutyczne do leczenia choroby alzheimera
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
IN2014MN02236A (es)
IN2015DN03854A (es)
IN2015DN01023A (es)
MX2018003685A (es) Moleculas tipo esfingolipidos sinteticas, farmacos, metodos de su sintesis y metodos de tratamiento.
UY35209A (es) Compuestos tricíclicos
PE20151424A1 (es) Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
NZ707773A (en) Methods of treating liver diseases
MX2015011588A (es) Tratamiento de combinacion.
BR112017003651A2 (pt) derivados de isoquinolinona úteis no tratamento de câncer
TR201906539T4 (tr) Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi.
GB201206984D0 (en) New therapeutic use
PE20151587A1 (es) Composicion farmaceutica que comprende al 3-carboxi-n-etil-n,n-dimetilpropein-1-aminio o una sal farmaceuticamente aceptable del mismo